Fundamental Analysis of GlaxoSmithKline PLC ADR - Growth / Value Index
GSK - Valuation Highlights
Valuation Analysis
Undervalued - Price to Intrinsic Value of 0.536
Tsr Value Index - Very Poor Score of 9.38
Price to Book Ratio of 14.72 suggesting that it is very expensive
Book Value in last 3 years is trending down
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Price to Earning | 41.18 | 30.45 | 63.13 % | |
| Price to Book | 14.50 | 14.45 | 58.85 % | 13.98 |
| Price to Sales | 6.01 | 6.10 | 94.66 % | |
| Enterprise Value to EBITDA Multiple | 13.47 | 26.18 | 112.50 % |
GSK - Profitability Highlights
Profitability Analysis
Piotroski F Score - Good Value of 7.0
Over the last 3 years, the company has achieved Incredible Return on Equity
Company Earning excess return
During the past twelve months, the company has given a strong Return On Equity of 34.58%
Reasonable Dividend Yield of 3.34 %
Annual Net Profit in last 3 years is trending up
Good Return On Capital Employed of 21.67
Good Net Margin of 14.59% is achieved by the company
Low Earning Yield of 2.39 %
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Return On Equity | 34.58 | 45.50 | -2.01 % | 7.56 |
| Return On Asset | 7.56 | 10.29 | 25.80 % | 1.79 |
| Net Profit Margin | 14.59 | 20.02 | 19.32 % | 14.21 |
| Operating Profit Margin | 23.18 | 27.49 | 25.29 % | 26.93 |
| EBITDA Margin | 25.54 | 25.06 | -17.19 % | 34.39 |
Highlights
| Market Cap | 91714.67 M |
| Enterprise Value | 105745 M |
| Price/Book TTM | 14.50 |
| Outstanding Share | 2039.01 M |
| Float/ Outstanding Share | 192.79% |
| Dividend Yield | 3.35 % |
Share Holding
Guru Numbers
| Price/Graham No | 5.14 |
| Peter Lynch Ratio | -0.939 |
| Piotroski F Score | 7.00 |
| Altman Z Score | 2.12 |
| Sloan Ratio | 0.0224 |
| Peter Lynch Fair Value | 0 |
GSK - Growth Highlights
Growth Analysis
Tsr Growth Index - Very Poor Score of 15.14
Company's Total Assets is Decreasing for last 3 years
Operating Cash Flow decreasing for last 3 year
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 30740.00 M | 3.42 % | 8.56 % |
| Gross Profit | 22338.00 M | 7.57 % | 5.04 % |
| EBITDA | 7850.00 M | 14.36 % | 13.54 % |
| Net Profit | 4484.00 M | 23.41 % | 198.86 % |
| EPS | 1.09 | 38.70 % | NA |
GSK - Stability Highlights
Stability Analysis
Debt to equity ratio has decreased and is lowest in last five years
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ |
|---|---|---|---|
| Debt to Equity Ratio | 1.27 | -35.81 % | 0.189 |
| Cash Ratio | 0.246 | -26.92 % | |
| Quick Ratio | 0.624 | -8.90 % | 0.580 |
| Shareholders Equity | 22.62 | 28.37 % | |
| Debt to EBITDA | 2.23 | -5.60 % |
Historical Valuation Ratios of GlaxoSmithKline PLC ADR
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of GlaxoSmithKline PLC ADR
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of GlaxoSmithKline PLC ADR
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of GlaxoSmithKline PLC ADR
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)